Save up to 30% on Elsevier print and eBooks with free shipping. No promo code needed.
Save up to 30% on print and eBooks.
Comprehensive Toxicology
2nd Edition - June 1, 2010
Editor: Charlene McQueen
Language: English
eBook ISBN:9780080468846
9 7 8 - 0 - 0 8 - 0 4 6 8 8 4 - 6
An explosive increase in the knowledge of the effects of chemical and physical agents on biological systems has led to an increased understanding of normal cellular functions an…Read more
Purchase options
LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
An explosive increase in the knowledge of the effects of chemical and physical agents on biological systems has led to an increased understanding of normal cellular functions and the consequences of their perturbations. The 14-volume Second Edition of Comprehensive Toxicology has been revised and updated to reflect new advances in toxicology research, including content by some of the leading researchers in the field. It remains the premier resource for toxicologists in academia, medicine, and corporations.
Comprehensive Toxicology Second Edition
provides a unique organ-systems structure that allows the user to explore the toxic effects of various substances on each human system, aiding in providing diagnoses and proving essential in situations where the toxic substance is unknown but its effects on a system are obvious. Comprehensive Toxicology Second Edition is the most complete and valuable toxicology work available to researchers today.
Contents updated and revised to reflect developments in toxicology research
Organized with a unique organ-system approach
Features full color throughout
Available electronically on sciencedirect.com, as well as in a limited-edition print version
Toxicology researchers, academic and medical practitioners, food science researchers, environmental researchers and consultants, forensic scientists, and occupational health and safety institutes
Charlene A. McQueen is a Professor in the Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona. Until January 2017, she was a Senior Scientist at the National Health Effects Research Laboratory of the USEPA. She served as the Director of the Integrated Systems Toxicology Division (2011-2016). Prior to that, she held positions at the Harrison School of Pharmacy, Auburn University (2007-2011) and the Department of Pharmacology and Toxicology at the University of Arizona (1990-2007). Dr McQueen received a M.S. in Pharmacology from New York University and Ph.D. in Human Genetics from the University of Michigan. Her work is in the areas of pharmacogenomics, toxicogenomics and chemical carcinogenesis. She has a particular interest in the genetic basis for response to xenobiotics. Her work with the arylamine N-acetyltransferase polymorphism has demonstrated that this genetic variation can affect drug efficacy as well as toxicity of aromatic amines and hydrazines. She was the Editor-in-Chief of the second edition of Comprehensive Toxicology and is continuing in that position for the third edition to be published in 2017. Dr McQueen is an American Association for the Advancement of Science (AAAS) Fellow and a Fellow in the Academy of Toxicological Sciences (ATS). Dr McQueen received the Society of Toxicology (SOT) Public Communications Award, the SOT AstraZeneca Traveling Lectureship Award and has served on numerous SOT committees. Dr McQueen was on the Environmental Health Sciences Committee of the National Institute of Environmental Health Sciences, the Board of Scientific Councilors of the National Toxicology Program and the National Institutes of Health Cancer Etiology Study Section. She is a member of the Editorial Board of the Reference Modules in Biomedical Sciences (Elsevier). Dr McQueen is a member of the Health and Environmental Sciences Institute (HESI) Board of Trustees, serving as the Board Secretary (2012-2017) and is currently Vice-president elect (2017-2018). Her current research interests include the discovery and development of Adverse Outcome Pathways (AOPs) for fatty liver disease and carcinogenesis as well as the role of the microbiome in xenobiotic biotransformation.
Affiliations and expertise
Department Head in Pharmacal Sciences, Auburn University